Capricor Therapeutics, Inc. , a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program for Duchenne Muscular Dystrophy using CAP-1002, Capricor's lead product candidate. CAP-1002 is an allogeneic, off-the-shelf, investigational cell therapy derived from donor heart tissue and is infused directly into a patient's coronary arteries during a catheterization procedure.
http://www.biospace.com/news_story.aspx?StoryID=348948&full=1
http://www.biospace.com/news_story.aspx?StoryID=348948&full=1
No comments:
Post a Comment